APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Federal policy relating to formulary placement of generic drugs and biosimilars; and S. 2333, the Pandemic and All-Hazards Preparedness Act, Title V, Section 501, Improving Notification Procedures In Case of Increased Demand for Critical Drugs, provisions relating to reporting the discontinuance of manufacturing drugs and active pharmaceutical ingredients.
Foreign entity interest: Apotex Pharmaceutical Holdings Inc., Artemis Intermediate Holdings Inc., and Artemis Parent Inc., the parent companies of Apotex Corp. identified by the registrants third quarter 2023 LD-2, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Manufacturing MAN
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; S. Amendment 532 to S. 2226, the National Defense Authorization Act, provisions relating to reviewing domestic biopharmaceutical manufacturing capabilities; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.
Foreign entity interest: Apotex Pharmaceutical Holdings Inc., Artemis Intermediate Holdings Inc., and Artemis Parent Inc., the parent companies of Apotex Corp. identified by the registrants third quarter 2023 LD-2, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| APOTEX PHARMACEUTICAL HOLDINGS INC. (APSHI) | Canada | Canada | 100.0% | — |
| ARTEMIS PARENT INC. | Canada | Canada | 100.0% | — |
| ARTEMIS INTERMEDIATE HOLDINGS INC. | Canada | Canada | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.